Cancer Research and Treatment

Original Articles

Association between Tumor Size at the Time of Disease Progression and Survival Outcomes: Chi Hoon Maeng, Bum Jun Kim, Myung-Ju Ahn, In Sil Choi, Dae Young Zang, Bo-Hyung Kim, Minji Kwon, Dae Seog Heo, Bhumsuk Keam; Received July 24, 2024 Accepted October 20, 2024 Published online October 22, 2024; DOI: https://doi.org/10.4143/crt.2024.690 [Accepted]

Abstract PDF: Purpose
This study evaluates the prognostic significance of tumor size at disease progression (PD) and depth of response (DOR) in cancer patients.
Materials and Methods
We performed post hoc analysis using data from six prospective clinical trials conducted by the Korean Cancer Study Group. Patients with tumor size at PD was categorized into ‘Mild PD’ and ‘Significant PD’ based on the cutoff values of relative change from baseline using maximally selected rank statistics. The overall survival (OS) and progression-free survival (PFS) were compared between PD and DOR categories.
Results
Among the 194 evaluable patients, 130 experienced PD. A 35.48% decrease from baseline in tumor size at PD was chosen for the cutoff between mild and significant PD for OS (mild PD: tumor size from the baseline ≤ −35.48%; significant PD > −35.48%). The mild PD had superior OS compared to the significant PD (25.8 vs. 12.8 months; Hazard ratio [HR] 0.47, 95% CI 0.266-0.843, p=0.009). When using an exploratory cutoff based on whether the tumor size was below vs. exceeded from the baseline (mild PD: tumor size from the baseline ≤ 0%; significant PD > 0%), OS remained significantly longer in the mild PD (17.1 vs. 11.8 months; HR 0.60, 95% CI 0.392-0.932, p=0.021). The greatest DOR was associated with the longest OS and PFS (p<0.001 for both).
Conclusion
Tumor size at PD and DOR were significant prognostic factors for progressive disease. Maintaining a sufficiently reduced tumor size even during PD was associated with better survival outcomes.

227 View
17 Download

The Survival and Financial Benefit of Investigator-Initiated Trials Conducted by Korean Cancer Study Group: Bum Jun Kim, Chi Hoon Maeng, Bhumsuk Keam, Young-Hyuck Im, Jungsil Ro, Kyung Hae Jung, Seock-Ah Im, Tae Won Kim, Jae Lyun Lee, Dae Seog Heo, Sang-We Kim, Keunchil Park, Myung-Ju Ahn, Byoung Chul Cho, Hoon-Kyo Kim, Yoon-Koo Kang, Jae Yong Cho, Hwan Jung Yun, Byung-Ho Nam, Dae Young Zang; Received April 30, 2024 Accepted July 8, 2024 Published online July 10, 2024; DOI: https://doi.org/10.4143/crt.2024.421 [Epub ahead of print]

Abstract PDF PubReader ePub: Purpose
The Korean Cancer Study Group (KCSG) is a nationwide cancer clinical trial group dedicated to advancing investigator-initiated trials (IITs) by conducting and supporting clinical trials. This study aims to review IITs conducted by KCSG and quantitatively evaluate the survival and financial benefits of IITs for patients.
Materials and Methods
We reviewed IITs conducted by KCSG from 1998 to 2023, analyzing progression-free survival (PFS) and overall survival (OS) gains for participants. PFS and OS benefits were calculated as the difference in median survival times between the intervention and control groups, multiplied by the number of patients in the intervention group. Financial benefits were assessed based on the cost of investigational products provided.
Results
From 1998 to 2023, KCSG conducted 310 IITs, with 133 completed and published. Of these, 21 were included in the survival analysis. The analysis revealed that 1,951 patients in the intervention groups gained a total of 2,558.4 months (213.2 years) of PFS and 2,501.6 months (208.5 years) of OS, with median gains of 1.31 months in PFS and 1.58 months in OS per patient. When analyzing only statistically significant results, PFS and OS gain per patients was 1.69 months and 3.02 months, respectively. Investigational drug cost analysis from six available IITs indicated that investigational products provided to 252 patients were valued at 10,400,077,294 won (approximately 8,046,481 US dollars), averaging about 41,270,148 won (approximately 31,930 US dollars) per patient.
Conclusion
Our findings, based on analysis of published research, suggest that IITs conducted by KCSG led to survival benefits for participants and, in some studies, may have provided financial benefits by providing investment drugs.

643 View
40 Download

Genitourinary cancer

TNM-Based Head-to-Head Comparison of Urachal Carcinoma and Urothelial Bladder Cancer: Stage-Matched Analysis of a Large Multicenter National Cohort: Sang Hun Song, Jaewon Lee, Young Hwii Ko, Jong Wook Kim, Seung Il Jung, Seok Ho Kang, Jinsung Park, Ho Kyung Seo, Hyung Joon Kim, Byong Chang Jeong, Tae-Hwan Kim, Se Young Choi, Jong Kil Nam, Ja Yoon Ku, Kwan Joong Joo, Won Sik Jang, Young Eun Yoon, Seok Joong Yun, Sung-Hoo Hong, Jong Jin Oh; Cancer Res Treat. 2023;55(4):1337-1345. Published online April 17, 2023; DOI: https://doi.org/10.4143/crt.2023.417

Abstract PDF Supplementary Material PubReader ePub

Purpose
Outcome analysis of urachal cancer (UraC) is limited due to the scarcity of cases and different staging methods compared to urothelial bladder cancer (UroBC). We attempted to assess survival outcomes of UraC and compare to UroBC after stage-matched analyses.
Materials and Methods
Total 203 UraC patients from a multicenter database and 373 UroBC patients in single institution from 2000 to 2018 were enrolled (median follow-up, 32 months). Sheldon stage conversion to corresponding TNM staging for UraC was conducted for head-to-head comparison to UroBC. Perioperative clinical variables and pathological results were recorded. Stage-matched analyses for survival by stage were conducted.
Results
UraC patients were younger (mean age, 54 vs. 67 years; p < 0.001), with 163 patients (80.3%) receiving partial cystectomy and 23 patients (11.3%) radical cystectomy. UraC was more likely to harbor ≥ pT3a tumors (78.8% vs. 41.8%). While 5-year recurrence-free survival, cancer-specific survival (CSS) and overall survival were comparable between two groups (63.4%, 67%, and 62.1% in UraC and 61.5%, 75.9%, and 67.8% in UroBC, respectively), generally favorable prognosis for UraC in lower stages (pT1-2) but unfavorable outcomes in higher stages (pT4) compared to UroBC was observed, although only 5-year CSS in ≥ pT4 showed statistical significance (p=0.028). Body mass index (hazard ratio [HR], 0.929), diabetes mellitus (HR, 1.921), pathologic T category (HR, 3.846), and lymphovascular invasion (HR, 1.993) were predictors of CSS for all patients.
Conclusion
Despite differing histology, UraC has comparable prognosis to UroBC with relatively favorable outcome in low stages but worse prognosis in higher stages. The presented system may be useful for future grading and risk stratification of UraC.

Citations

Citations to this article as recorded by

Clinical Presentation and Targeted Interventions in Urachal Adenocarcinoma: A Single-Institution Case Series and Review of Emerging Therapies
Akshay Mathavan, Akash Mathavan, Rodrigo Murillo-Alvarez, Kriti Gera, Urszula Krekora, Aaron J. Winer, Mohit Mathavan, Ellery Altshuler, Brian Hemendra Ramnaraign
Clinical Genitourinary Cancer.2024; 22(1): 67. CrossRef
Robotic‐assisted approaches to urachal carcinoma: A comprehensive systematic review of the safety and efficacy outcomes
Caio Vinícius Suartz, Lucas Motta Martinez, Pedro Henrique Brito, Carlos Victori Neto, Maurício Dener Cordeiro, Luiz Antonio Assan Botelho, Fábio Pescarmona Gallucci, José Maurício Mota, William Carlos Nahas, Leopoldo Alves Ribeiro‐Filho
BJUI Compass.2024; 5(3): 327. CrossRef

3,351 View
204 Download
2 Web of Science
2 Crossref

Lung cancer

Active Treatment Improves Overall Survival in Extremely Older Non–Small Cell Lung Cancer Patients: A Multicenter Retrospective Cohort Study: Su Yeon Lee, Yoon-Ki Hong, Wonjun Ji, Jae Cheol Lee, Chang Min Choi, Korean Association for Lung Cancer, Korea Central Cancer Registry; Cancer Res Treat. 2021;53(1):104-111. Published online October 5, 2020; DOI: https://doi.org/10.4143/crt.2020.894

Abstract PDF Supplementary Material PubReader ePub

Purpose
As the aging of society progresses, the proportion of extremely older lung cancer patients has also increased; However, studies of these patients with non–small cell lung cancer are limited. Therefore, we investigated the initial treatment modalities and survival outcomes for patients aged 80 years or over.
Materials and Methods
We included a multicenter retrospective cohort from the Korean Association for Lung Cancer Registry, which surveys 10% of the newly diagnosed lung cancer patients across 52 hospitals in Korea. We analyzed and compared the 2014–2016 data of the non–small cell lung cancer patients aged ≥ 80 years and those aged < 80 years.
Results
Of the 6,576 patients reviewed, 780 patients were aged ≥ 80 years, and 5,796 patients were aged < 80 years. In the patients aged ≥ 80 years, surgery and radiation therapy resulted in longer patient survival among those with a resectable tumor (stage I–II) than the best supportive care (median survival, not reached [surgery] vs. 32.2 months [radiation therapy] vs. 11.43 months [best supportive care]). The duration of survival in patients with advanced-stage (IV) lung cancers was higher after chemotherapy than after the best supportive care (median survival, 8.63 months vs. 2.5 months). Patients with stage IV adenocarcinoma who received targeted therapy had better survival than those who did not (median survival, 9.0 months vs. 4.3 months).
Conclusion
Even in extremely older patients, active treatments, such as surgery, radiation therapy, and chemotherapy, can result in better survival outcomes than the best supportive care.

Citations

Citations to this article as recorded by

ADENOCARCINOMA PULMONAR - ASPECTOS EPIDEMIOLÓGICOS, FISIOPATOLÓGICOS E TERAPÊUTICOS
Marcelo Vinicius Pereira Silva, Elizeu Augusto de Freitas Junior, Allan Martins de Oliveira, Elaine Timm, Mariana Brito Siqueira, Mônica Stefany Martelli, Elielson Mendonça de Oliveira, Victor Cavalcante Machado, Igor Vinicius Barbino Ferrari, Pamella Hag
Revista Contemporânea.2024; 4(5): e4464. CrossRef
Association between clinical outcomes and local treatment in stage IV non‐small cell lung cancer patients with single extrathoracic metastasis
Jeong Uk Lim, Hye Seon Kang, Ah Young Shin, Chang Dong Yeo, Chan Kwon Park, Sang Haak Lee, Seung Joon Kim
Thoracic Cancer.2022; 13(9): 1349. CrossRef
Characteristics and clinical outcomes of patients with nonsmoking small cell lung cancer in Korea
Hye Seon Kang, Jung Uk Lim, Chang Dong Yeo, Chan Kwon Park, Sang Haak Lee, Seung Joon Kim, Ho Cheol Kim, Chang Min Choi, Chi Young Jung, Deog Gon Cho, Jae Hyun Jeon, Jeong Eun Lee, Jin Seok Ahn, Yeongdae Kim, Yoo-Duk Choi, Yang-Gun Suh, Jung-Eun Kim, Youn
BMC Pulmonary Medicine.2022;[Epub] CrossRef

6,591 View
147 Download
3 Web of Science
3 Crossref

Chemotherapy versus Best Supportive Care in Advanced Biliary Tract Carcinoma: A Multi-institutional Propensity Score Matching Analysis: Jun Ho Ji, Young Saing Kim, Inkeun Park, Soon Il Lee, Rock Bum Kim, Joon Oh Park, Sung Yong Oh, In Gyu Hwang, Joung-Soon Jang, Haa-Na Song, Jung-Hun Kang; Cancer Res Treat. 2018;50(3):791-800. Published online August 23, 2017; DOI: https://doi.org/10.4143/crt.2017.044

Abstract PDF PubReader ePub

Purpose
Although chemotherapy is recommended by various guidelines for advanced biliary tract cancer (BTC), the evidence supporting its use over best supportive care (BSC) is limited. The aim of this study was to investigate the survival benefit of chemotherapy over that of BSC in advanced BTC patients.
Materials and Methods
Advanced BTC patientswith a good performance status (Eastern CooperativeOncologyGroup [ECOG] 0-2) were eligible for the study. Data were retrospectively collected from four tertiary cancer centers and analyzed using propensity score matching (PSM). Of the 604 patients enrolled, 206 received BSC and 398 received chemotherapy. PSM analysis was performed using the following variables: age, ECOG status, carcinoembryonic antigen (CEA) level, white blood cell level, albumin level, total bilirubin level, and aspartate aminotransferase level. The sample size of each group was 164 patients after PSM. Median survival was compared between the two groups by using the Kaplan-Meier method, and prognostic factors were investigated using Cox proportional regression analysis.
Results
In post-PSM analysis, the respective median survival for the chemotherapy and BSC groups was dependent on the following prognostic factors: total population, 12.0 months vs. 7.5 months (p=0.001); locally advanced disease, 16.7 months vs. 13.4 months (p=0.490); cancer antigen 19-9 ≤ 100 IU/mL, 12.7 months vs. 10.6 months (p=0.330); and CEA ≤ 3.4 ng/mL, 17.1 months vs. 10.6 months (p=0.052).
Conclusion
Chemotherapy improved overall survival of patients with advanced BTC who had a good performance status. However, this survival benefit was not observed in BTC patients with locally advanced disease or with lower tumor marker. Individualized approach is needed for initiation of palliative chemotherapy in advanced BTC.

Citations

Citations to this article as recorded by

National guidelines for the diagnosis and treatment of hilar cholangiocarcinoma
Faisal Saud Dar, Zaigham Abbas, Irfan Ahmed, Muhammad Atique, Usman Iqbal Aujla, Muhammad Azeemuddin, Zeba Aziz, Abu Bakar Hafeez Bhatti, Tariq Ali Bangash, Amna Subhan Butt, Osama Tariq Butt, Abdul Wahab Dogar, Javed Iqbal Farooqi, Faisal Hanif, Jahanzai
World Journal of Gastroenterology.2024; 30(9): 1018. CrossRef
Treatment patterns and survival in older adults with unresected nonmetastatic biliary tract cancers
Ali Belkouz, Elise de Savornin Lohman, Jyothi R. Thumma, Bas Groot Koerkamp, Philip R. de Reuver, Martijn G.H. van Oijen, Cornelis J.A. Punt, Hari Nathan, Heinz-Josef Klümpen
Journal of Geriatric Oncology.2023; 14(3): 101447. CrossRef
Main causes of death in advanced biliary tract cancer
Kana Kimura‐Seto, Yasushi Kojima, Shiori Komori, Yuya Hisada, Yuki Otake, Yuka Yanai, Akiko Saito, Naoki Akazawa, Yasuo Tanaka, Chizu Yokoi, Mikio Yanase, Junichi Akiyama, Natsuyo Yamamoto, Kazuhiko Yamada
Cancer Medicine.2023; 12(9): 10889. CrossRef
A Systematised Literature Review of Real-World Treatment Patterns and Outcomes in Unresectable Advanced or Metastatic Biliary Tract Cancer
Vivian Peirce, Michael Paskow, Lei Qin, Ruby Dadzie, Maria Rapoport, Samantha Prince, Sukhvinder Johal
Targeted Oncology.2023; 18(6): 837. CrossRef
Short- and Long-Term Survival of Metastatic Biliary Tract Cancer in the United States From 2000 to 2018
Van Nghiem, Sarah Wood, Rekha Ramachandran, Grant Williams, Darryl Outlaw, Ravikumar Paluri, Young-il Kim, Olumide Gbolahan
Cancer Control.2023;[Epub] CrossRef
Anticancer Drugs Compared to No Anticancer Drugs in Patients with Advanced Hepatobiliary Cancer: A Mapping Review and Evidence Gap Map
Carolina Requeijo, Javier Bracchiglione, Nicolás Meza, Roberto Acosta-Dighero, Josefina Salazar, Marilina Santero, Adriana-G Meade, María Jesús Quintana, Gerardo Rodríguez-Grijalva, Anna Selva, Ivan Solà, Gerard Urrútia, Xavier Bonfill Cosp
Clinical Epidemiology.2023; Volume 15: 1069. CrossRef

8,158 View
213 Download
8 Web of Science
6 Crossref

Pretreatment Serum Amyloid A and C-reactive Protein Comparing with Epstein-Barr Virus DNA as Prognostic Indicators in Patients with Nasopharyngeal Carcinoma: A Prospective Study: Qiu-Yan Chen, Qing-Nan Tang, Lin-Quan Tang, Wen-Hui Chen, Shan-Shan Guo, Li-Ting Liu, Chao-Feng Li, Yang Li, Yu-Jing Liang, Xue-Song Sun, Ling Guo, Hao-Yuan Mo, Rui Sun, Dong-Hua Luo, Yu-Ying Fan, Yan He, Ming-Yuan Chen, Ka-Jia Cao, Chao-Nan Qian, Xiang Guo, Hai-Qiang Mai; Cancer Res Treat. 2018;50(3):701-711. Published online July 14, 2017; DOI: https://doi.org/10.4143/crt.2017.180

Abstract PDF Supplementary Material PubReader ePub

Purpose
The measuring Epstein-Barr virus (EBV) DNA is an important predictor of nasopharyngeal carcinoma (NPC). This study evaluated the predictive value of pretreatment serum amyloid A (SAA) and C-reactive protein (CRP) comparing with EBV DNA in patients with NPC.
Materials and Methods
In an observational study of 419 non-metastatic NPC patients, we prospectively evaluated the prognostic effects of pretreatment SAA, CRP, and EBV DNA on survival. The primary endpoint was progress-free survival (PFS).
Results
The median level of SAA and CRP was 4.28 mg/L and 1.88 mg/L, respectively. For the highSAA group (> 4.28 mg/L) versus the low-SAA (≤ 4.28 mg/L) group and the high-CRP group (> 1.88 mg/L) versus the low-CRP (≤ 1.88 mg/L) group, the 5-year PFS was 64.5% versus 73.1% (p=0.013) and 65.2% versus 73.3% (p=0.064), respectively. EBV DNA detection showed a superior predictive result, the 5-year PFS in the EBV DNA ≥ 1,500 copies/mL group was obviously different than the EBV DNA < 1,500 copies/mL group (62.2% versus 77.8%, p < 0.001). Multifactorial Cox regression analysis confirmed that in the PFS, the independent prognostic factors were including EBV DNA (hazard ratio [HR], 1.788; p=0.009), tumour stage (HR, 1.903; p=0.021), and node stage (HR, 1.498; p=0.049), but the SAA and CRP were not included in the independent prognostic factors.
Conclusion
The results of SAA and CRP had a certain relationship with the prognosis of NPC, and the prognosis of patients with high level of SAA and CRP were poor. However, the predictive ability of SAA and CRP was lower than that of EBV DNA.

Citations

Citations to this article as recorded by

Development and application of a serious adverse events risk model for concurrent chemoradiotherapy in patients with nasopharyngeal carcinoma
Jiahui Li, Qianwen Liu, Huiying Qin
Medicine.2024; 103(34): e39377. CrossRef
Selection of induction chemotherapy cycles for stage N3 nasopharyngeal carcinoma based on pre-treatment plasma EBV DNA
Youliang Weng, Sunqin Cai, Chao Li, Yun Xu, Yuhui Pan, Zongwei Huang, Ying Li, Zijie Wu, Yu Chen, Sufang Qiu
Scientific Reports.2024;[Epub] CrossRef
Maintenance therapy improves the survival outcomes of patients with metastatic nasopharyngeal carcinoma responding to first-line chemotherapy: a multicentre, randomized controlled clinical study
Ying Lu, Haixin Huang, Hui Yang, Xiaohua Hu, Meilian Liu, Changjie Huang, Xianbin Feng, Xishan Chen, Zhou Jiang
Journal of Cancer Research and Clinical Oncology.2023; 149(8): 4327. CrossRef
Association of Epstein–Barr virus DNA and SAA with S1 maintenance therapy outcomes in patients with metastatic nasopharyngeal carcinoma
Ying Lu, Zhou Jiang, Huan Lin, Hui Yang, Xishan Chen, Haixin Huang
Future Oncology.2022; 18(22): 2441. CrossRef
Long‐term monitoring of dynamic changes in plasma EBV DNA for improved prognosis prediction of nasopharyngeal carcinoma
Wanxia Li, Jing Chen, Bijun Liang, Zonghua Li, Junzheng Li, Xiaofei Yuan, Shuting Wu, Fangfang Zeng, Xinyu Peng, Yanfei Li, Juan Lu, Feipeng Zhao, Xiong Liu
Cancer Medicine.2021; 10(3): 883. CrossRef
A systematic review and recommendations on the use of plasma EBV DNA for nasopharyngeal carcinoma
Anne W.M. Lee, Victor H.F. Lee, Wai-Tong Ng, Primož Strojan, Nabil F. Saba, Alessandra Rinaldo, Stefan M. Willems, Juan P. Rodrigo, Arlene A. Forastiere, Alfio Ferlito
European Journal of Cancer.2021; 153: 109. CrossRef
Prognostic value of Epstein–Barr virus DNA level for nasopharyngeal carcinoma: a meta-analysis of 8128 cases
Hongling Qu, Yuli Huang, Shufen Zhao, Yuanqing Zhou, Weibiao Lv
European Archives of Oto-Rhino-Laryngology.2020; 277(1): 9. CrossRef
The prognostic value of integration of pretreatment serum amyloid A (SAA)–EBV DNA (S‐D) grade in patients with nasopharyngeal carcinoma
Jianpei Li, Changchun Lai, Songguo Peng, Hao Chen, Lei Zhou, Yufeng Chen, Shulin Chen
Clinical and Translational Medicine.2020;[Epub] CrossRef
Utility of a Simple Scoring System in Differentiating Bacterial Infections in Cases of Fever of Unknown Origin
Teng Xu, Li Wang, Shi Wu, Fenfen Zhou, Haihui Huang
Clinical Infectious Diseases.2020; 71(Supplement): S409. CrossRef
The prognostic value of serum amyloid A in solid tumors: a meta-analysis
Hai-yingjie Lin, Guo-qiang Tan, Yan Liu, Shao-qiang Lin
Cancer Cell International.2019;[Epub] CrossRef
Molecular Prognostic Value of Circulating Epstein–Barr Viral DNA in Nasopharyngeal Carcinoma: A Meta-Analysis of 27,235 Cases in the Endemic Area of Southeast Asia
Xulin Xie, Yupei Ren, Kun Wang, Bin Yi
Genetic Testing and Molecular Biomarkers.2019; 23(7): 448. CrossRef
Rapid detection of quantum dot immune chromatography nasopharyngeal carcinoma EBNA1 antibody
Jian He, Jing Xu, Ping Wu, Lingfeng Liao, Huatao Quan, Jing Kang, Yongquan Tian, Yaoyun Tang
Oncology Letters.2018;[Epub] CrossRef

9,186 View
268 Download
15 Web of Science
12 Crossref

Education Level Is a Strong Prognosticator in the Subgroup Aged More Than 50 Years Regardless of the Molecular Subtype of Breast Cancer: A Study Based on the Nationwide Korean Breast Cancer Registry Database: Ki-Tae Hwang, Woochul Noh, Se-Heon Cho, Jonghan Yu, Min Ho Park, Joon Jeong, Hyouk Jin Lee, Jongjin Kim, Sohee Oh, Young A Kim, Korean Breast Cancer Society; Cancer Res Treat. 2017;49(4):1114-1126. Published online February 2, 2017; DOI: https://doi.org/10.4143/crt.2016.528

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study investigated the role of the education level (EL) as a prognostic factor for breast cancer and analyzed the relationship between the EL and various confounding factors.
Materials and Methods
The data for 64,129 primary breast cancer patients from the Korean Breast Cancer Registry were analyzed. The EL was classified into two groups according to the education period; the high EL group (≥ 12 years) and low EL group (< 12 years). Survival analyses were performed with respect to the overall survival between the two groups.
Results
A high EL conferred a superior prognosis compared to a low EL in the subgroup aged > 50 years (hazard ratio, 0.626; 95% confidence interval [CI], 0.577 to 0.678) but not in the subgroup aged ≤ 50 years (hazard ratio, 0.941; 95% CI, 0.865 to 1.024). The EL was a significant independent factor in the subgroup aged > 50 years according to multivariate analyses. The high EL group showed more favorable clinicopathologic features and a higher proportion of patients in this group received lumpectomy, radiation therapy, and endocrine therapy. In the high EL group, a higher proportion of patients received chemotherapy in the subgroups with unfavorable clinicopathologic features. The EL was a significant prognosticator across all molecular subtypes of breast cancer.
Conclusion
The EL is a strong independent prognostic factor for breast cancer in the subgroup aged > 50 years regardless of the molecular subtype, but not in the subgroup aged ≤ 50 years. Favorable clinicopathologic features and active treatments can explain the main causality of the superior prognosis in the high EL group.

Citations

Citations to this article as recorded by

Risk factors for intensive care unit readmission after lung transplantation: a retrospective cohort study
Hye-Bin Kim, Sungwon Na, Hyo Chae Paik, Hyeji Joo, Jeongmin Kim
Acute and Critical Care.2021; 36(2): 99. CrossRef
Educational disparities in nasopharyngeal carcinoma survival: Temporal trends and mediating effects of clinical factors
Wang‐Zhong Li, Guo‐Ying Liu, Shu‐Hui Lv, Sen‐Kui Xu, Hu Liang, Kui‐Yuan Liu, Meng‐Yun Qiang, Xi Chen, Xiang Guo, Xing Lv, Wei‐Xiong Xia, Yan‐Qun Xiang
Clinical and Translational Medicine.2020;[Epub] CrossRef
Education level as a predictor of survival in patients with multiple myeloma
Limei Xu, Xiuju Wang, Xueyi Pan, Xiaotao Wang, Qing Wang, Bingyi Wu, Jiahui Cai, Ying Zhao, Lijuan Chen, Wuping Li, Juan Li
BMC Cancer.2020;[Epub] CrossRef
Prognostic influence of Korean public medical insurance system on breast cancer patients
Ki-Tae Hwang, Young Wook Ju, Young A Kim, Jongjin Kim, Sohee Oh, Jiwoong Jung, Young Jun Chai, In Sil Choi, So Won Oh
Annals of Surgical Treatment and Research.2019; 96(2): 58. CrossRef

9,407 View
170 Download
5 Web of Science
4 Crossref

Patient’s Factors at Entering Hospice Affecting Length of Survival in a Hospice Center: Guk Jin Lee, Hye Shin Ahn, Se Eun Go, Ji Hyun Kim, Min Wu Seo, Seung Hun Kang, Yeo Ree Yang, Mi Yeong Lee, Ku Ock Lee, Sang Hoon Chun, Jong Youl Jin; Cancer Res Treat. 2015;47(1):1-8. Published online August 28, 2014; DOI: https://doi.org/10.4143/crt.2013.148

Abstract PDF PubReader ePub

Purpose
In order to provide effective hospice care, adequate length of survival (LOS) in hospice is necessary. However the reported average LOS is much shorter. Analysis of LOS in hospice has not been reported from Korea. We evaluated the duration of LOS and the factors associated with LOS at our hospice center.
Materials and Methods
We retrospectively examined 446 patients who were admitted to our hospice unit between January 2010 and December 2012. We performed univariate and multivariate analysis for analysis of factors associated with LOS.
Results
The median LOS was 9.5 days (range, 1 to 186 days). The LOS of 389 patients (86.8%) was< 1 month. At the time of admission to hospice, 112 patients (25.2%) were completely bedridden, 110 patients (24.8%) had mouth care only without intake, and 134 patients (30.1%) had decreased consciousness, from confusion to coma. The median time interval between the day of the last anticancer treatment and the day of hospice admission was 75 days. By analysis of the results of multivariate analysis, decreased intake and laboratory results showing increased total white blood cell (WBC), decreased platelet count, increased serum creatinine, increased aspartate aminotransferase (AST), alanine aminotransferase (ALT), and lactate dehydrogenase (LDH) level were poor prognostic factors for survival in hospice.
Conclusion
Before hospice admission, careful evaluation of the patient’s performance, particularly the oral intake, and total WBC, platelet, creatinine, AST, ALT, and LDH level is essential, because these were strong predictors of shorter LOS. In the future, conduct of prospective controlled studies is warranted in order to confirm the relationship between potential prognostic factors and LOS in hospice.

Citations

Citations to this article as recorded by

Changes in the palliative performance scale may be as important as the initial palliative performance scale for predicting survival in terminal cancer patients
Guk Jin Lee, Ji Hyun Gwak, Myoung Sim Kim, Mi Yeong Lee, Seo Ree Kim, Sang Hoon Chun, Jong Youl Jin
Palliative and Supportive Care.2021; 19(5): 547. CrossRef
Safety, Efficacy, and Patient Satisfaction with Initial Peripherally Inserted Central Catheters Compared with Usual Intravenous Access in Terminally Ill Cancer Patients: A Randomized Phase II Study
Eun Ju Park, Kwonoh Park, Jae-Joon Kim, Sang-Bo Oh, Ki Sun Jung, So Yeon Oh, Yun Jeong Hong, Jin Hyeok Kim, Joo Yeon Jang, Ung-Bae Jeon
Cancer Research and Treatment.2021; 53(3): 881. CrossRef
Hypernatremia at admission predicts poor survival in patients with terminal cancer: a retrospective cohort study
Min-Seok Seo, In Cheol Hwang, Jaehun Jung, Hwanhee Lee, Jae Hee Choi, Jae-Yong Shim
BMC Palliative Care.2020;[Epub] CrossRef
The Impact of Combined Use of Opioids, Antipsychotics, and Anxiolytics on Survival in the Hospice Setting
Marin Golčić, Renata Dobrila-Dintinjana, Goran Golčić, Aleksandar Čubranić
Journal of Pain and Symptom Management.2018; 55(1): 22. CrossRef
Cancer-related hypercalcemia in oral cancer
T.-C. Lin, K.-L. Liang, L.-C. Lee, C.-Y. Hsu, T.-T. Yen
International Journal of Oral and Maxillofacial Surgery.2018; 47(6): 685. CrossRef
Physical Exercise: An Evaluation of a New Clinical Biomarker of Survival in Hospice Patients
Marin Golčić, Renata Dobrila-Dintinjana, Goran Golčić, Lidija Gović-Golčić, Aleksandar Čubranić
American Journal of Hospice and Palliative Medicine®.2018; 35(11): 1377. CrossRef
Effects of a new medical insurance payment system for hospice patients in palliative care programs in Korea
Youngin Lee, Seung Hun Lee, Yun Jin Kim, Sang Yeoup Lee, Jeong Gyu Lee, Dong Wook Jeong, Yu Hyeon Yi, Young Jin Tak, Hye Rim Hwang, Mieun Gwon
BMC Palliative Care.2018;[Epub] CrossRef
Prediction of Patient Discharge Status Based on Indicators on Admission
Sung-In Chung, Seung Hun Lee, Yun-Jin Kim, Sang-Yeoup Lee, Jeong-Gyu Lee, Yu-Hyeon Yi, Young-Hye Cho, Young-Jin Tak, Hye-Rim Hwang, Eun-Ju Park, Kyung-Mi Kim
The Korean Journal of Hospice and Palliative Care.2018; 21(3): 75. CrossRef
Amyotrophic Lateral Sclerosis Survival Score (ALS-SS): A simple scoring system for early prediction of patient survival
Christian Lunetta, Andrea Lizio, Mario Giovanni Melazzini, Eleonora Maestri, Valeria A. Sansone
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration.2016; 17(1-2): 93. CrossRef
Safety, efficacy, and patient-perceived satisfaction of peripherally inserted central catheters in terminally ill cancer patients: a prospective multicenter observational study
Kwonoh Park, Hyun Jung Jun, So Yeon Oh
Supportive Care in Cancer.2016; 24(12): 4987. CrossRef

12,221 View
78 Download
9 Web of Science
10 Crossref

Loss of DNA-dependent Protein Kinase Catalytic Subunit (DNA-PKcs) Expression in Gastric Cancers: Hye Seung Lee, Han-Kwang Yang, Woo Ho Kim, Gheeyoung Choe; Cancer Res Treat. 2005;37(2):98-102. Published online April 30, 2005; DOI: https://doi.org/10.4143/crt.2005.37.2.98

Abstract PDF PubReader ePub

Purpose

DNA-PKcs is one of the DNA repair genes. It was recently found that hyperplasia and dysplasia of the intestinal mucosa and the production of aberrant crypt foci were developed in DNA-PKcs-null mice, and this suggests a suppressive role for DNA-PKcs in tumorigenesis.

Materials and Methods

To investigate the possible relationship between the clinico-pathologic characteristics and the survival of gastric cancer patients, the expression status of DNA-PKcs was determined in 279 consecutive gastric cancers. Immunohistochemical analysis was performed to evaluate the expression levels of DNA-PKcs protein by using the tissue array method.

Results

Out of 279 consecutive gastric cancers, 63 cases (22.6%) showed the loss of DNA-PKcs expression. The loss of DNA-PKcs expression was significantly associated with advanced cancer (p<0.001), lymphatic invasion (p=0.001), lymph node metastasis (p=0.009), and advanced pTNM stage (p=0.009). Univariate survival analysis revealed that patients with the loss of DNA-PKcs expression had significantly poorer survival than those patients with intact DNA-PKcs expression (p=0.004). Moreover, the loss of DNA-PKcs expression was identified to correlate with a lower survival in the subgroup of stage I gastric cancer patients (p=0.037).

Conclusion

The loss of DNA-PKcs expression was found in 23% of human gastric cancers and this was identified to significantly correlate with poor patient survival, especially for stage I gastric cancer patients.

Citations

Citations to this article as recorded by

Shaping DNA damage responses: Therapeutic potential of targeting telomeric proteins and DNA repair factors in cancer
Yu Bin Ng, Semih Can Akincilar
Current Opinion in Pharmacology.2024; 76: 102460. CrossRef
An exosome mRNA-related gene risk model to evaluate the tumor microenvironment and predict prognosis in hepatocellular carcinoma
Zhonghai Du, Xiuchen Han, Liping Zhu, Li Li, Leandro Castellano, Justin Stebbing, Ling Peng, Zhiqiang Wang
BMC Medical Genomics.2024;[Epub] CrossRef
Secrets of DNA-PKcs beyond DNA repair
Sydney Camfield, Sayan Chakraborty, Shailendra Kumar Dhar Dwivedi, Pijush Kanti Pramanik, Priyabrata Mukherjee, Resham Bhattacharya
npj Precision Oncology.2024;[Epub] CrossRef
Small molecule DNA-PK inhibitors as potential cancer therapy: a patent review (2010–present)
Suwen Hu, Zi Hui, Frédéric Lirussi, Carmen Garrido, Xiang-Yang Ye, Tian Xie
Expert Opinion on Therapeutic Patents.2021; 31(5): 435. CrossRef
Role of PRKDC in cancer initiation, progression, and treatment
Yu Chen, Yi Li, Jiani Xiong, Bin Lan, Xuefeng Wang, Jun Liu, Jing Lin, Zhaodong Fei, Xiaobin Zheng, Chuanben Chen
Cancer Cell International.2021;[Epub] CrossRef
Comparative proteomic analysis of different stages of breast cancer tissues using ultra high performance liquid chromatography tandem mass spectrometer
Abdullah Saleh Al-wajeeh, Salizawati Muhamad Salhimi, Majed Ahmed Al-Mansoub, Imran Abdul Khalid, Thomas Michael Harvey, Aishah Latiff, Mohd Nazri Ismail, John Matthew Koomen
PLOS ONE.2020; 15(1): e0227404. CrossRef
PRKDC: new biomarker and drug target for checkpoint blockade immunotherapy
Kien Thiam Tan, Chun-Nan Yeh, Yu-Chan Chang, Jen-Hao Cheng, Wen-Liang Fang, Yi-Chen Yeh, Yu-Chao Wang, Dennis Shin-Shian Hsu, Chiao-En Wu, Jiun-I Lai, Peter Mu-Hsin Chang, Ming-Han Chen, Meng-Lun Lu, Shu-Jen Chen, Yee Chao, Michael Hsiao, Ming-Huang Chen
Journal for ImmunoTherapy of Cancer.2020; 8(1): e000485. CrossRef
DNA-PK in human malignant disorders: Mechanisms and implications for pharmacological interventions
Michaela Medová, Matúš Medo, Lusine Hovhannisyan, Carmen Muñoz-Maldonado, Daniel M. Aebersold, Yitzhak Zimmer
Pharmacology & Therapeutics.2020; 215: 107617. CrossRef
DNA-dependent protein kinase: Epigenetic alterations and the role in genomic stability of cancer
Vazhappilly Cijo George, Shabbir Ahmed Ansari, Vipin Shankar Chelakkot, Ayshwarya Lakshmi Chelakkot, Chaithanya Chelakkot, Varsha Menon, Wafaa Ramadan, Kannatt Radhakrishnan Ethiraj, Raafat El-Awady, Theodora Mantso, Melina Mitsiogianni, Mihalis I. Panagi
Mutation Research/Reviews in Mutation Research.2019; 780: 92. CrossRef
Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer
Xiang Zhang, Yanlin Wang, Yuan Ning
Urologic Oncology: Seminars and Original Investigations.2017; 35(3): 111.e15. CrossRef
Ab initio and QSAR study of several etoposides as anticancer drugs: Solvent effect
R. Sayyadi kord Abadi, A. Alizadehdakhel, S. Dorani Shiraz
Russian Journal of Physical Chemistry B.2017; 11(2): 307. CrossRef
The Role of the Core Non-Homologous End Joining Factors in Carcinogenesis and Cancer
Brock Sishc, Anthony Davis
Cancers.2017; 9(7): 81. CrossRef
PRKDC regulates chemosensitivity and is a potential prognostic and predictive marker of response to adjuvant chemotherapy in breast cancer patients
Gang Sun, Le Yang, Chao Dong, Bin Ma, Meihui Shan, Binlin Ma
Oncology Reports.2017; 37(6): 3536. CrossRef
DNA-PKcs activates the Chk2–Brca1 pathway during mitosis to ensure chromosomal stability
Z Shang, L Yu, Y-F Lin, S Matsunaga, C-Y Shen, B P C Chen
Oncogenesis.2014; 3(2): e85. CrossRef
Adverse prognostic and predictive significance of low DNA-dependent protein kinase catalytic subunit (DNA-PKcs) expression in early-stage breast cancers
Tarek Abdel-Fatah, Arvind Arora, Devika Agarwal, Paul Moseley, Christina Perry, Nicola Thompson, Andrew R. Green, Emad Rakha, Stephen Chan, Graham Ball, Ian O. Ellis, Srinivasan Madhusudan
Breast Cancer Research and Treatment.2014; 146(2): 309. CrossRef
Predictive factors for the sensitivity of radiotherapy and prognosis of esophageal squamous cell carcinoma
Shaobin Wu, Xianwei Wang, Jin-Xiang Chen, Yuxiang Chen
International Journal of Radiation Biology.2014; 90(5): 407. CrossRef
DNA-PKcs and Ku70 are Predictive Markers for Poor Prognosis of Patients With Gall Bladder Malignancies
Feng Ren, Zhu-lin Yang, Xingguo Tan, Dongcai Liu, Qiong Zou, Yuan Yuan, Jinghe Li, Lufeng Liang, Guixiang Zeng, Senlin Chen
Applied Immunohistochemistry & Molecular Morphology.2014; 22(10): 741. CrossRef
Deregulation of DNA-dependent protein kinase catalytic subunit contributes to human hepatocarcinogenesis development and has a putative prognostic value
M Evert, M Frau, M L Tomasi, G Latte, M M Simile, M A Seddaiu, A Zimmermann, S Ladu, T Staniscia, S Brozzetti, G Solinas, F Dombrowski, F Feo, R M Pascale, D F Calvisi
British Journal of Cancer.2013; 109(10): 2654. CrossRef
Expression of DNA-PKcs and BRCA1 as prognostic indicators in nasopharyngeal carcinoma following intensity-modulated radiation therapy
JIAO YANG, XIMING XU, YANRONG HAO, JIAXIN CHEN, HEMING LU, JIAN QIN, LUXING PENG, BIAO CHEN
Oncology Letters.2013; 5(4): 1199. CrossRef
Identification of genes with a correlation between copy number and expression in gastric cancer
Lei Cheng, Ping Wang, Sheng Yang, Yanqing Yang, Qing Zhang, Wen Zhang, Huasheng Xiao, Hengjun Gao, Qinghua Zhang
BMC Medical Genomics.2012;[Epub] CrossRef
Lack of the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs) is accompanied by increased CK2α′ levels
Birgitte B. Olsen, Ulrike Fischer, Tine L. Rasmussen, Matthias Montenarh, Eckart Meese, Gerhard Fritz, Olaf-Georg Issinger
Molecular and Cellular Biochemistry.2011; 356(1-2): 139. CrossRef
The association of DNA-dependent protein kinase activity of peripheral blood lymphocytes with prognosis of cancer
M Someya, K-i Sakata, Y Matsumoto, R P Kamdar, M Kai, M Toyota, M Hareyama
British Journal of Cancer.2011; 104(11): 1724. CrossRef
Tissue Array Methods for High-throughput Clinicopathologic Research
Hye Seung Lee, Woo Ho Kim
Cancer Research and Treatment.2006; 38(1): 1. CrossRef

9,830 View
64 Download
23 Crossref

Prognostic Significance of CD24 Expression in Gastric Carcinoma: Nevine S. Darwish, Min A Kim, Mee Soo Chang, Hye Seung Lee, Byung Lan Lee, Yong Il Kim, Woo Ho Kim; Cancer Res Treat. 2004;36(5):298-302. Published online October 30, 2004; DOI: https://doi.org/10.4143/crt.2004.36.5.298

Abstract PDF PubReader ePub

Purpose

The human CD24 antigen is a small heavily glycosylated cell surface protein, which is expressed in hematological malignancies, as well as in a large variety of solid tumors. Its expression is now known to be related to the prognosis of several kinds of tumors. This study is designed to examine the prognostic significance of CD24 in Korean gastric cancer patients.

Materials and Methods

In the present study, we examined CD24 expression in 300 consecutive cases of gastric carcinoma by immunohistochemical staining using the tissue-array method. We also investigated the clinicopathological profiles related to CD24 expression.

Results

One hundred and three cases out of 300 (34.3%) showed the positive expression of CD24. The altered expression of CD24 was significantly associated with differentiated cancer (p=0.003), the intestinal subtype according to the Lauren classification (p<0.001), the advanced stage cancer (p=0.027), with lymphatic invasion (p=0.038) and with vascular invasion (p=0.006). The survival analysis revealed that the patients with CD24 positive expression showed significantly poorer survival than those without CD24 expression. Moreover, a combined evaluation revealed that PTEN+/CD24- cases showed the best survival compared to other groups (p=0.01).

Conclusion

Positive CD24 expression occurs in a subset of gastric carcinomas and it correlates significantly with lymphatic invasion, blood vessel invasion and poor survival.

Citations

Citations to this article as recorded by

CD24 blockade as a novel strategy for cancer treatment
Yawen Wang, Haoran Yu, Mengyuan Yu, Hui Liu, Bing Zhang, Yuanyuan Wang, Simin Zhao, Qingxin Xia
International Immunopharmacology.2023; 121: 110557. CrossRef
Emerging Immune Checkpoint Molecules on Cancer Cells: CD24 and CD200
Sun Young Moon, Minjoo Han, Gyoungah Ryu, Seong-Ah Shin, Jun Hyuck Lee, Chang Sup Lee
International Journal of Molecular Sciences.2023; 24(20): 15072. CrossRef
Clinical and prognostic significances of cancer stem cell markers in gastric cancer patients: a systematic review and meta-analysis
Mahdieh Razmi, Roya Ghods, Somayeh Vafaei, Maryam Sahlolbei, Leili Saeednejad Zanjani, Zahra Madjd
Cancer Cell International.2021;[Epub] CrossRef
Exosomes and GPI-anchored proteins: Judicious pairs for investigating biomarkers from body fluids
Michel Vidal
Advanced Drug Delivery Reviews.2020; 161-162: 110. CrossRef
CD24, A Review of its Role in Tumor Diagnosis, Progression and Therapy
Yang-Hong Ni, Xia Zhao, Wei Wang
Current Gene Therapy.2020; 20(2): 109. CrossRef
DNA Aptamers for the Malignant Transformation Marker CD24
Joanna Fafińska, Andreas Czech, Tobias Sitz, Zoya Ignatova, Ulrich Hahn
Nucleic Acid Therapeutics.2018; 28(6): 326. CrossRef
The Identifications and Clinical Implications of Cancer Stem Cells in Colorectal Cancer
S.M. Riajul Wahab, Farhadul Islam, Vinod Gopalan, Alfred King-yin Lam
Clinical Colorectal Cancer.2017; 16(2): 93. CrossRef
Clinicopathological and Prognostic Value of CD24 Expression in Breast Cancer: A Meta-Analysis
Gao Liu, Guo-Xing Liu, Yu Fang, Zhen-Yu Cao, Hui-Hui Du, Jie Fu, Ke Qian
The International Journal of Biological Markers.2017; 32(2): 182. CrossRef
CD24 associates with EGFR and supports EGF/EGFR signaling via RhoA in gastric cancer cells
Wenjie Deng, Luo Gu, Xiaojie Li, Jianchao Zheng, Yujie Zhang, Biao Duan, Jie Cui, Jing Dong, Jun Du
Journal of Translational Medicine.2016;[Epub] CrossRef
CD24 enrichment protects while its loss increases susceptibility of juvenile chondrocytes towards inflammation
Jieun Lee, Piera Smeriglio, Jason Dragoo, William J. Maloney, Nidhi Bhutani
Arthritis Research & Therapy.2016;[Epub] CrossRef
CD44v3+/CD24− cells possess cancer stem cell-like properties in human oral squamous cell carcinoma
KEITA TODOROKI, SACHIKO OGASAWARA, JUN AKIBA, MASAMICHI NAKAYAMA, YOSHIKI NAITO, NAOKO SEKI, JINGO KUSUKAWA, HIROHISA YANO
International Journal of Oncology.2016; 48(1): 99. CrossRef
CD44 and CD24 coordinate the reprogramming of nasopharyngeal carcinoma cells towards a cancer stem cell phenotype through STAT3 activation
Yao-An Shen, Chia-Yu Wang, Hui-Yen Chuang, John Jeng-Jong Hwang, Wei-Hsin Chi, Chih-Hung Shu, Ching-Yin Ho, Wing-Yin Li, Yann-Jang Chen
Oncotarget.2016; 7(36): 58351. CrossRef
CD24 Overexpression Is Associated with Poor Prognosis in Luminal A and Triple-Negative Breast Cancer
Mi Jeong Kwon, Jinil Han, Ji Hyun Seo, Kyoung Song, Hae Min Jeong, Jong-Sun Choi, Yu Jin Kim, Seon-Heui Lee, Yoon-La Choi, Young Kee Shin, Yves St-Pierre
PLOS ONE.2015; 10(10): e0139112. CrossRef
Expression of CD24, p21, p53, and c‐myc in alpha‐fetoprotein‐producing gastric cancer: Correlation with clinicopathologic characteristics and survival
Xiaowen Liu, Hongmei Yu, Hong Cai, Yanong Wang
Journal of Surgical Oncology.2014; 109(8): 859. CrossRef
CD24 mediates gastric carcinogenesis and promotes gastric cancer progression via STAT3 activation
Ying-Chao Wang, Ji-Lin Wang, Xuan Kong, Tian-Tian Sun, Hao-Yan Chen, Jie Hong, Jing-Yuan Fang
Apoptosis.2014; 19(4): 643. CrossRef
CD44 but not CD24 expression is related to poor prognosis in non-cardia adenocarcinoma of the stomach
Xueyuan Cao, Donghui Cao, MeiShan Jin, Zhifang Jia, Fei Kong, Hongxi Ma, Yinping Wang, Jing Jiang
BMC Gastroenterology.2014;[Epub] CrossRef
Hypoxia‐mediated CD24 expression is correlated with gastric cancer aggressiveness by promoting cell migration and invasion
Nobuaki Fujikuni, Hideki Yamamoto, Kazuaki Tanabe, Yutaka Naito, Naoya Sakamoto, Yuka Tanaka, Kazuyoshi Yanagihara, Naohide Oue, Wataru Yasui, Hideki Ohdan
Cancer Science.2014; 105(11): 1411. CrossRef
Clinicopathological and Prognostic Significance of CD24 Overexpression in Patients with Gastric Cancer: A Meta-Analysis
Jing-Xun Wu, Yuan-Yuan Zhao, Xuan Wu, Han-Xiang An, Yitao Ding
PLoS ONE.2014; 9(12): e114746. CrossRef
Biomarkers for predicting future metastasis of human gastrointestinal tumors
Lui Ng, Ronnie Tung Ping Poon, Roberta Pang
Cellular and Molecular Life Sciences.2013; 70(19): 3631. CrossRef
CD44/CD24 Expression in recurrent gastric cancer: a retrospective analysis
Ching-Shya Yong, Chih-Ming Ou Yang, Yenn-Hwei Chou, Chao-Sheng Liao, Chung-Wei Lee, Chin-Cheng Lee
BMC Gastroenterology.2012;[Epub] CrossRef
PTEN deletion is rare but often homogeneous in gastric cancer
Sormeh Mina, Benjamin A Bohn, Ronald Simon, Antje Krohn, Matthias Reeh, Dirk Arnold, Carsten Bokemeyer, Guido Sauter, Jakob R Izbicki, Andreas Marx, Phillip R Stahl
Journal of Clinical Pathology.2012; 65(8): 693. CrossRef
Prognostic significance of loss of c-fos protein in gastric carcinoma
Seon Pil Jin, Ji Hun Kim, Min A Kim, Han-Kwang Yang, Hee Eun Lee, Hye Seung Lee, Woo Ho Kim
Pathology & Oncology Research.2007; 13(4): 284. CrossRef
Tissue Array Methods for High-throughput Clinicopathologic Research
Hye Seung Lee, Woo Ho Kim
Cancer Research and Treatment.2006; 38(1): 1. CrossRef
Loss of DNA-dependent Protein Kinase Catalytic Subunit (DNA-PKcs) Expression in Gastric Cancers
Hye Seung Lee, Han-Kwang Yang, Woo Ho Kim, Gheeyoung Choe
Cancer Research and Treatment.2005; 37(2): 98. CrossRef
Cytoplasmic CD24 Expression in Colorectal Cancer Independently Correlates with Shortened Patient Survival
Wilko Weichert, Carsten Denkert, Mick Burkhardt, Tserenchunt Gansukh, Joachim Bellach, Peter Altevogt, Manfred Dietel, Glen Kristiansen
Clinical Cancer Research.2005; 11(18): 6574. CrossRef

9,513 View
61 Download
25 Crossref

First
Prev
Page of 1
Next
Last

Search